BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company’s Scientific Advisory Board (SAB) with three leading viral infectious disease experts. The SAB will provide strategic and scientific counsel to BlueWillow’s clinical programs.
BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the immune system via the nasal mucosa, with Porton […]
BlueWillow Biologics announced today that NanoBio Protect, the over-the-counter nasal antiseptic launched in 2020, is no longer for sale in the U.S. “The decision to withdraw the product from the market was made in April 2021. At that time, it was delisted from Amazon and distributors/retailers were notified that marketing support for the product was […]
Research indicates that intranasal administration is effective at stimulating the mucosal immunity response. Preclinical study shows positive serum and mucosal immune response. Tapei, Taiwan & ANN ARBOR, Michigan, November 10, 2020 – Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, […]
BlueWillow Biologics today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application for the company’s next-generation anthrax vaccine candidate. The Phase 1 clinical study is expected to begin enrollment in late 2019.
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, has been awarded a Fast Track Small Business Research Innovation contract from the National Institute of Allergy and Infectious Diseases for development of an intranasal therapeutic peanut allergy vaccine.
BlueWillow Biologics® today announced the company has been recognized as one of the 2019 “Cool Places to Work in Michigan” by Crain’s Detroit.
BlueWillow Biologics® today announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the development of an intranasal NanoVax® herpes simplex virus (HSV) vaccine.
BlueWillow Biologics® today announced the issuance of U.S. patent number 10,138,279 covering an intranasal NanoVax® anthrax vaccine.
BlueWillow Biologics® today announced the company has been awarded an NIH Small Business Innovation Research (SBIR) grant for the development of an intranasal NanoVax® vaccine for the prevention of chlamydia.
BlueWillow announces the issuance of a patent to the University of Michigan, under exclusive license to BlueWillow, which allows use of BlueWillow’s NanoVax® platform with tumor antigens to create novel therapeutic vaccines that could potentially generate immune responses to treat existing cancers.
NanoBio Corporation, a clinical-stage biopharmaceutical company, today announced that it has changed its corporate name to BlueWillow Biologics® in conjunction with the closing of a $10 million Series A financing. The financing round was led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.
University of Michigan Researchers Show Intranasal NanoVax Vaccination Suppresses Peanut Allergies in Mice
BlueWillow’s intranasal NanoVax vaccination protected mice from allergic reactions when exposed to peanut, according to U-M researchers.
NanoBio Corporation today announced the progression of a novel intranasal anthrax vaccine into a pre-clinical IND-enabling toxicology study funded by the U.S. National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
NanoBio Corporation today announced that it has been awarded a two-year Phase II Small Business Research Innovation (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for the development of an intranasal nanoemulsion (NE) adjuvanted vaccine for the prevention of genital herpes.
NanoBio Corporation today announced the issuance of a patent which broadly covers the composition of NanoBio’s intramuscular and intranasal RSV vaccine candidates, combining the company’s innovative nanoemulsion (NE) adjuvant with strain L19 of RSV.
NanoBio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
NanoBio Corporation today announced that the company will present key data at the Mucosal Immunology Course & Symposium Meeting (MICS) in Toronto, demonstrating the advantages of its intranasal nanoemulsion (NE) adjuvant for use in the development of vaccines for pertussis.
NanoBio to Present Data Demonstrating Benefit of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine
NanoBio Corporation will present key data demonstrating the advantages of its nanoemulsion (NE) adjuvant for use in the development of intramuscular vaccines for pandemic influenza and other diseases,at the GTCbio 14th Vaccines Research & Development Conference on June 3, 2016.
NanoBio’s Genital Herpes Vaccine Demonstrates Efficacy in Guinea Pigs as Both a Prophylactic and a Therapeutic Vaccine
NanoBio Corporation today announced that its intranasal nanoemulsion (NE) adjuvanted genital herpes vaccine has demonstrated efficacy in studies conducted in both the prophylactic and the therapeutic guinea pig model. The data was recently presented at the 40th Annual International Herpesvirus Workshop in Boise, ID.
NanoBio to Present Data Demonstrating the Potential for its Intranasal Vaccine to Protect Against Genital Herpes Infection
NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014. The Company’s presentation will highlight the advantages of its nanoemulsion (NE) adjuvant in the development of a prophylactic genital herpes vaccine that induces protection by eliciting both systemic and mucosal immune responses.